Home Cart Sign in  
Chemical Structure| 2095393-15-8 Chemical Structure| 2095393-15-8

Structure of ARQ 531
CAS No.: 2095393-15-8

Chemical Structure| 2095393-15-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity.

Synonyms: Nemtabrutinib; MK-1026

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ARQ 531

CAS No. :2095393-15-8
Formula : C25H23ClN4O4
M.W : 478.93
SMILES Code : ClC1=C(C(C2=CN=C3C2=C(N[C@H]4CO[C@H](CO)CC4)NC=N3)=O)C=CC(OC5=CC=CC=C5)=C1
Synonyms :
Nemtabrutinib; MK-1026
MDL No. :MFCD31692379
InChI Key :JSFCZQSJQXFJDS-QAPCUYQASA-N
Pubchem ID :129045720

Safety of ARQ 531

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ARQ 531

RTK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03162536 Lymphoma, B-Cell|Small Lymphoc... More >>ytic Lymphoma|Chronic Lymphocytic Leukemia|Waldenstrom Macroglobulinemia|Mantle Cell Lymphoma|Diffuse Large B Cell Lymphoma|Richter's Transformation|Follicular Lymphoma|Marginal Zone Lymphoma Less << PHASE1|PHASE2 ACTIVE_NOT_RECRUITING 2025-09-15 Mayo Clinic Hospital ( Site 01... More >>40), Scottsdale, Arizona, 85259, United States|UCLA Hematology & Oncology ( Site 0017), Los Angeles, California, 90095, United States|Colorado Blood Cancer Institute ( Site 0225), Denver, Colorado, 80218, United States|University of Michigan ( Site 0018), Ann Arbor, Michigan, 48109, United States|Mayo Clinic - Rochester ( Site 0138), Rochester, Minnesota, 58905, United States|Duke Cancer Center ( Site 0067), Durham, North Carolina, 27710, United States|The Ohio State University Wexner Medical Center ( Site 0056), Columbus, Ohio, 43210, United States|Tennessee Oncology, PLLC ( Site 0020), Nashville, Tennessee, 37203, United States|UT Southwestern Medical Center ( Site 0116), Dallas, Texas, 75390-8562, United States|University of Utah, Huntsman Cancer Institute ( Site 0122), Salt Lake City, Utah, 84112, United States Less <<
NCT06586671 Hematological Malignancy PHASE1 COMPLETED 2023-11-13 QPS-MRA, LLC-Early Phase (Site... More >> 0002), South Miami, Florida, 33143, United States Less <<
NCT06772805 Healthy PHASE1 COMPLETED 2023-12-12 Labcorp Clinical Research Unit... More >> Inc. (Site 0001), Honolulu, Hawaii, 96813, United States Less <<
NCT06442436 Hepatic Impairment (HI) PHASE1 RECRUITING 2025-08-08 Clinical Pharmacology of Miami... More >> ( Site 0003), Miami, Florida, 33014-3616, United States|Orlando Clinical Research Center ( Site 0001), Orlando, Florida, 32809, United States|Texas Liver Institute ( Site 0002), San Antonio, Texas, 78215, United States Less <<
NCT06772818 Healthy PHASE1 COMPLETED 2024-02-16 Labcorp Clinical Research Unit... More >> Inc. (Site 0001), Honolulu, Hawaii, 96813, United States Less <<
NCT05347225 Hematological Malignancies PHASE1 ACTIVE_NOT_RECRUITING 2027-04-30 Guangdong Provincial People's ... More >>Hospital-hematology department ( Site 1002), Guangzhou, Guangdong, 510000, China|SUN YAT-SEN UNIVERSITY CANCER CENTRE-Internal medicine ( Site 1007), Guangzhou, Guangdong, 511400, China|Henan Cancer Hospital-hematology department ( Site 1003), Zhengzhou, Henan, 450008, China|Hunan Cancer Hospital ( Site 1004), Changsha, Hunan, 410013, China|Institute of hematology&blood disease hospital-Hematology ( Site 1001), Tianjin, Tianjin, 300020, China Less <<
NCT05673460 Mature B-cell Neoplasms PHASE1 ACTIVE_NOT_RECRUITING 2026-03-30 Nagoya University Hospital ( S... More >>ite 0003), Nagoya, Aichi, 466-8560, Japan|National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, 2778577, Japan|Kindai University Hospital ( Site 0006), Osakasayama, Osaka, 589-8511, Japan|Chiba Cancer Center ( Site 0005), Chiba, 260-8717, Japan|Kyushu University Hospital ( Site 0008), Fukuoka, 812-8582, Japan|Okayama University Hospital ( Site 0007), Okayama, 700-8558, Japan|Yamagata University Hospital ( Site 0001), Yamagata, 990-9585, Japan Less <<
NCT04728893 Hematologic Malignancies|Walde... More >>nstroms Macroglobulinaemia|Non-Hodgkins Lymphoma|Chronic Lymphocytic Leukaemia Less << PHASE2 RECRUITING 2027-03-19 Highlands Oncology Group ( Sit... More >>e 2728), Springdale, Arkansas, 72762, United States|University of California San Diego Moores Cancer Center ( Site 2717), La Jolla, California, 92093-0698, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site, Torrance, California, 90502, United States|Colorado Blood Cancer Institute ( Site 2726), Denver, Colorado, 80218, United States|The University of Louisville, James Graham Brown Cancer Center ( Site 2729), Louisville, Kentucky, 40202, United States|Mayo Clinic - Rochester ( Site 2706), Rochester, Minnesota, 55905, United States|Astera Cancer Care ( Site 2732), East Brunswick, New Jersey, 08816, United States|John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704), Hackensack, New Jersey, 07601, United States|Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708), Fargo, North Dakota, 58122, United States|UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730), Dallas, Texas, 75390, United States|Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane, Washington, 99208, United States|Hospital Aleman ( Site 0102), Ciudad Autonoma de Buenos Aires, Buenos Aires, C1118AAT, Argentina|Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103), Buenos Aires, Caba, C1431FWO, Argentina|Fundacion Estudios Clinicos ( Site 0112), Rosario, Santa Fe, S2000DEJ, Argentina|FUNDALEU ( Site 0104), Caba, C1114AAN, Argentina|Hospital Privado Universitario de Córdoba ( Site 0107), Cordoba, X5016KEH, Argentina|Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110), Mendoza, M5500AYB, Argentina|Nepean Hospital-Nepean Cancer Care Centre ( Site 0204), Sydney, New South Wales, 2747, Australia|Box Hill Hospital ( Site 0203), Box Hill, Victoria, 3128, Australia|Sir Charles Gairdner Hospital ( Site 0200), Nedlands, Western Australia, 6009, Australia|Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303), S?o Paulo, Sao Paulo, 05403-000, Brazil|Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300), Rio de Janeiro, 20231-050, Brazil|BP - A Beneficencia Portuguesa de S?o Paulo ( Site 0302), Sao Paulo, 01321-001, Brazil|Hospital Paulistano - Amil Clinical Research ( Site 0311), Sao Paulo, 01321-001, Brazil|Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401), Calgary, Alberta, T2N 5G2, Canada|The Ottawa Hospital ( Site 0404), Ottawa, Ontario, K1H 8L6, Canada|Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406), Toronto, Ontario, M5G 2M9, Canada|CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403), Montreal, Quebec, H1T 2M4, Canada|Jewish General Hospital ( Site 0400), Montreal, Quebec, H3T 1E2, Canada|Anhui Provincial Hospital ( Site 2808), Hefei, Anhui, 230071, China|Peking University Third Hospital-Hematology ( Site 2827), Beijing, Beijing, 100191, China|The Second Affiliated Hospital of Chongqing Medical University ( Site 2825), Chongqing, Chongqing, 400072, China|Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824), Guangzhou, Guangdong, 510060, China|Guangxi Medical University - Liuzhou Renmin Hospital ( Site 2817), Liuzhou, Guangxi, 545006, China|Guangxi Medical University Affiliated Tumor Hospital ( Site 2814), Nanning, Guangxi, 530021, China|Henan Cancer Hospital-hematology department ( Site 2802), Zhengzhou, Henan, 450008, China|Wuhan Union Hospital ( Site 2816), Wuhan, Hubei, 430010, China|The Second Xiangya Hospital of Central South University ( Site 2820), Changsha, Hunan, 410011, China|Hunan Cancer Hospital ( Site 2822), Changsha, Hunan, 410013, China|Jiangsu Province Hospital ( Site 2823), Nanjing, Jiangsu, 210029, China|The Affiliated Hospital of Xuzhou Medical College ( Site 2818), Xuzhou, Jiangsu, 221000, China|The First Affiliated Hospital of Nanchang University ( Site 2815), Nanchang, Jiangxi, 330006, China|The First Hospital of Jilin University-Hematology ( Site 2803), Changchun, Jilin, 130021, China|Fudan University Shanghai Cancer Center ( Site 2801), Shanghai, Shanghai, 200032, China|Huashan Hospital, Fudan University ( Site 2821), Shanghai, Shanghai, 200040, China|West China Hospital Sichuan University ( Site 2810), Cheng Du, Sichuan, 610041, China|Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio, Tianjin, Tianjin, 301617, China|The First Affiliated Hospital, Zhejiang University ( Site 2826), Hangzhou, Zhejiang, 310002, China|Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600), Brno, Brno-mesto, 625 00, Czechia|Fakultni nemocnice Hradec Kralove ( Site 0601), Hradec Kralove, 50005, Czechia|Aarhus University Hospital ( Site 0702), Aarhus N, Midtjylland, 8200, Denmark|Aalborg Universitetshospital ( Site 0703), Aalborg, Nordjylland, 9000, Denmark|Sjaellands Universitetshospital Roskilde ( Site 0701), Roskilde, Sjaelland, 4000, Denmark|Odense University Hospital ( Site 0705), Odense C, Syddanmark, 5000, Denmark|Centre Hospitalier Universitaire de Nice - H?pital l'Archet ( Site 0810), Nice, Alpes-Maritimes, 06202, France|Institut Paoli-Calmettes ( Site 0803), Marseille, Bouches-du-Rhone, 13009, France|Centre Hospitalier Lyon-Sud ( Site 0804), Pierre Benite, Rhone-Alpes, 69495, France|Centre Hospitalier de Versailles ( Site 0809), Le Chesnay, Yvelines, 78150, France|Hopital Saint Louis ( Site 0805), Paris, 75010, France|Universitaetsklinikum Ulm ( Site 0906), Ulm, Baden-Wurttemberg, 89081, Germany|Universitaetsklinikum Koeln ( Site 0901), Koeln, Nordrhein-Westfalen, 50937, Germany|St. Marien-Krankenhaus Siegen ( Site 0914), Siegen, Nordrhein-Westfalen, 57072, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 0902), Dresden, Sachsen, 01307, Germany|Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202), Pecs, Baranya, 7624, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 1201), Debrecen, Hajdu-Bihar, 4032, Hungary|Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206), Nyiregyhaza, Szabolcs-Szatmar-Bereg, 4400, Hungary|Orszagos Onkologiai Intezet ( Site 1200), Budapest, 1122, Hungary|Beaumont Hospital ( Site 2900), Dublin, Dublin 9, Ireland|University Hospital Limerick ( Site 2903), Limerick, V94 F858, Ireland|Ha Emek Medical Center ( Site 1305), Afula, 1834111, Israel|Soroka Medical Center ( Site 1307), Beer-Sheva, 8410101, Israel|Rambam Medical Center ( Site 1301), Haifa, 3109601, Israel|Hadassah Ein Karem Jerusalem ( Site 1300), Jerusalem, 9112001, Israel|Chaim Sheba Medical Center ( Site 1302), Ramat Gan, 5262001, Israel|Kaplan Medical Center ( Site 1304), Rehovot, 7610001, Israel|Sourasky Medical Center ( Site 1303), Tel Aviv, 6423906, Israel|Istituto Tumori Giovanni Paolo II ( Site 1409), Bari, 70124, Italy|A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400), Bologna, 40138, Italy|ASST Spedali Civili di Brescia ( Site 1408), Brescia, 25123, Italy|IRCCS Ospedale San Raffaele ( Site 1402), Milano, 20132, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403), Napoli, 80131, Italy|Fondazione IRCCS Policlinico San Matteo ( Site 1407), Pavia, 27100, Italy|IRCCS - Arcispedale Santa Maria Nuova ( Site 1405), Reggio Emilia, 42123, Italy|Policlinico Umberto I ( Site 1404), Roma, 00161, Italy|Severance Hospital Yonsei University Health System ( Site 2201), Seoul, 03722, Korea, Republic of|Samsung Medical Center ( Site 2200), Seoul, 06351, Korea, Republic of|Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site, Wroclaw, Dolnoslaskie, 50-367, Poland|Pratia MCM Krakow ( Site 1601), Krakow, Malopolskie, 30-727, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site, Warszawa, Mazowieckie, 02-781, Poland|Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607), Opole, Opolskie, 45-061, Poland|Szpitale Pomorskie Sp. z o.o. ( Site 1600), Gdynia, Pomorskie, 81-519, Poland|Spitalul Clinic Col?ea ( Site 1805), Bucure?ti, Bucuresti, 030171, Romania|Ovidius Clinical Hospital ( Site 1804), Ovidiu, Constanta, 905900, Romania|Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802), Brasov, 500052, Romania|Institutul Regional de Oncologie Iasi ( Site 1801), Iasi, 700483, Romania|Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000), Hospitalet de Llobregat, Barcelona, 08908, Spain|Hospital Universitario de Salamanca ( Site 2002), Salamanca, Castilla Y Leon, 37007, Spain|CHUAC-Complejo Hospitalario Universitario A Coru?a ( Site 2005), A Coru?a, La Coruna, 15006, Spain|Hospital General Universitario de Alicante ( Site 2007), Alicante, 03010, Spain|Hospital Universitari Vall d'Hebron ( Site 2001), Barcelona, 08035, Spain|Hospital Universitario 12 de Octubre ( Site 2003), Madrid, 28041, Spain|Inselspital Bern ( Site 2303), Bern, Berne, 3010, Switzerland|Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302), Bellinzona, Ticino, 6500, Switzerland|Mega Medipol-Hematology ( Site 2406), Stanbul, Istanbul, 34214, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400), Ankara, 06590, Turkey|VKV Amerikan Hastanesi ( Site 2403), Istanbul, 34365, Turkey|Sisli Florence Nightingale Hastanesi ( Site 2407), Istanbul, 34381, Turkey|Dokuz Eylül üniversitesi-Hematology ( Site 2402), Izmir, 35340, Turkey|MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( S, Cherkassy, Cherkaska Oblast, 18009, Ukraine|Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510), Ivano-Frankivsk, Ivano-Frankivska Oblast, 76008, Ukraine|Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506), Lviv, Lvivska Oblast, 79044, Ukraine|National Cancer Institute ( Site 2507), Kyiv, 03022, Ukraine|Kyiv City Clinical Hospital 9 ( Site 2502), Kyiv, 04112, Ukraine|Bristol Haematology and Oncology Centre ( Site 2610), Bristol, Bristol, City Of, BS2 8ED, United Kingdom|Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601), Nottingham, England, NG5 1PF, United Kingdom|GenesisCare - Windsor ( Site 2608), Windsor, England, SL4 3HD, United Kingdom|Sarah Cannon Research Institute UK ( Site 2612), London, London, City Of, W1G 6AD, United Kingdom|GenesisCare - Oxford ( Site 2607), Oxford, Oxfordshire, OX4 6LB, United Kingdom|GenesisCare - Cambridge ( Site 2611), Newmarket, Suffolk, CB8 7XN, United Kingdom|The Royal Marsden NHS Foundation Trust. ( Site 2606), Sutton, Surrey, SM2 5PT, United Kingdom|The Christie NHS Foundation Trust ( Site 2602), Manchester, M20 4BX, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.44mL

2.09mL

1.04mL

20.88mL

4.18mL

2.09mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories